2018 Conference Program


Sunday, September 30, 2018  

8:30 am - 8:45 am

Welcome

8:45 am - 11:45 am

Session 1: Regulating T Cells and Their Response to Cancer

Session Chairperson: Christoph Huber, Association for Cancer Immunotherapy (CIMT), Mainz, Germany

Rafi Ahmed, Emory University, Atlanta, Georgia

Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

W. Nicholas Haining, Dana-Farber Cancer Institute, Boston, Massachusetts

Nicholas P. Restifo, National Cancer Institute, NIH, Bethesda, Maryland

11:45 am - 2:15 pm

Lunch & Poster Session

The following topics will be presented:       

  • Clinical Trials of Cancer Immunotherapies
  • Convergence of Technology and Cancer Immunotherapy
  • Genetically Engineered T Cells
  • Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
  • Microbiome and Metabolism
  • Mutational Analysis and Predicting Response to Immunotherapy
  • Novel Vaccine Platforms and Combinations
  • Regulating T Cells and Their Response to Cancer
  • Tackling the Tumor Microenvironment - Beyond T Cells
  • Trials in Progress
  • Other                                                     

2:15 pm - 2:45 pm

William B. Coley Lecture

Padmanee Sharma, The University of Texas M.D. Anderson Cancer Center
From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy

2:45 pm - 6:15 pm

Session 2: Tackling the Tumor Microenvironment           

Session Chairperson: Wolf H. Fridman, Centre de Recherche des Cordeliers, Paris, France and Dmitry Gabrilovich, The Wistar Institute, Philadelphia, PA

Shannon J. Turley, Genentech, S. San Francisco, California
Stromal activation in cancer immunology and immunotherapy

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Leonid S. Metelitsa, Baylor College of Medicine, Houston, Texas
Harnessing natural and engineered properties of NKT cells for cancer immunotherapy

Dmitry Gabrilovich, The Wistar Institute, Philadelphia, Pennsylvania
PMN-MDSC and neutrophils: Tale of two cells in cancer


monday, october 1, 2018

8:15 am - 8:45 am

Keynote Address

Ignacio Melero, Universidad de Navarra, University Clinic and CIMA, Pamplona, Spain
The immunotherapy faces of Interleukin-8 and CD137

8:45 am - 12:15 pm

Session 3: Genetically Engineered T Cells

Session Co-Chairpersons: Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA and Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY

James N. Kochenderfer, National Cancer Institute, NIH, Bethesda, Maryland
CAR T-cell therapy for lymphoma and multiple myeloma 

Crystal L. Mackall, Stanford University School of Medicine, Stanford, California

Steven A. Rosenberg, National Cancer Institute, NIH, Bethesda, Maryland
Cell transfer immunotherapy targeting unique somatic mutations in cancer

Christine E. Brown, City of Hope National Medical Center, Duarte, California 

Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington
Utilizing synthetic biology and high-dimensional probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors

12:45 pm - 2:15 pm

Lunch

2:15 pm - 5:45 pm

Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Session Co-Chairpersons: Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France and Ellen Puré, University of Pennsylvania, Philadelphia, PA

Alberto Bardelli, University of Turin and Candiolo Cancer Institute, Candiolo, Italy
Inactivation of DNA repair to improve immune surveillance

David L. Porter, University of Pennsylvania, Philadelphia, Pennsylvania
CAR T cells: On the road to a cure

Peter Savas, Peter MacCallum Cancer Centre, Melbourne, Australia
Targeting the immune microenvironment in breast cancer.

Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Antony Rosen, Johns Hopkins University School of Medicine, Baltimore, Maryland
Autoimmune rheumatic diseases and cancer


tuesDAY, october 2, 2018

8:15 am - 12:45 pm

Session 5: Novel Vaccine Platforms and Combinations

Session Co-Chairpersons: Nina Bhardwaj, Icahn School of Medicine at Mt. Sinai, New York, NY and Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals, Leiden, The Netherlands

Robert D. Schreiber, Washington University School of Medicine, St. Louis, Missourri

Ugur Sahin, BioNTech, Mainz, Germany

Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Targeting tumor neoantigens to drive effective tumor immunity

Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands
Combination immunotherapy of cancer caused by human papilloma virus

Alan Melcher, The Institute of Cancer Research, London, United Kingdom
Oncolytic viruses: Potential for in situ anti-tumor vaccination and combination with checkpoint blockade

James J. Moon, University of Michigan, Ann Arbor, Michigan
Nanodisc platform technology for cancer vaccination

Robert Seder, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland
Peptide-TLR-7/8 agonist conjugate vaccines chemically programmed for nanoparticle self-assembly to enhance the magnitude and breadth of anticancer neoantigen CD8 T cell immunity

12:45 pm - 3:15 pm

Lunch & Poster Session

The following topics will be presented:

  • Clinical Trials of Cancer Immunotherapies
  • Convergence of Technology and Cancer Immunotherapy
  • Genetically Engineered T Cells
  • Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
  • Microbiome and Metabolism
  • Mutational Analysis and Predicting Response to Immunotherapy
  • Novel Vaccine Platforms and Combinations
  • Regulating T Cells and Their Response to Cancer
  • Tackling the Tumor Microenvironment - Beyond T Cells
  • Trials in Progress
  • Other

3:15 pm - 6:45 pm

Session 6: Mutational Analysis and Predicting Response to Immunotherapy

Session Co-Chairpersons: Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands and Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, Maryland

Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands
T cell recognition in human cancer’

Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai, New York, New York

Naiyer Rizvi, Columbia University Medical Center, New York, New York

Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, Maryland

Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
Mapping immune recognition of non-self neoantigens in human pancreatic cancer


wednesday, october 3, 2018

8:15 am - 10:45 am

Session 7: Convergence of Technology and Cancer Immunotherapy

Session Co-Chairpersons: Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands and Özlem Türeci, Ganymed Pharmaceuticals, Mainz, Germany

Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, Massachusetts
Determinants of effective tumor immunity

Dan Dongeun Huh, University of Pennsylvania, Philadelphia, Pennsylvania

Darrell Irvine, MIT/Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts
Enhancing the function of CAR T cells via a universal vaccine strategy

10:45 am - 12:45 pm

Session 8: Microbiome and Metabolism

Session Co-Chairpersons: Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France and Laurence Zitvogel, Institut Gustave Roussy, Paris, France

Hassane M. Zarour, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Manipulating the gut microbiome to improve immunotherapy of melanoma

Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas

Yasmine Belkaid, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland

All sessions will include proffered presentations selected from the submitted abstracts. There will also be a 30 min. refreshment break each morning and afternoon.


Continuing Medical EdUcation (CME)

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians. AACR has designated this live activity for a maximum of 24.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.